Strata Skin Sciences, Inc.

Greetings and welcome to the Strata Skin Sciences third quarter earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Rich Cockrell of Investor Relations. Thank you, Rich. You may begin.

Good morning, everyone, and thank you for joining us today. Earlier today, Strata Skin Sciences released its financial results for the third quarter ended September 30th, 2023. A copy of that release is available on the company's website. Now, before we begin, I'd like to remind everyone that comments made by management during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, remarks about future expectations, plans, and prospects for the company. We encourage you to review the company's filings with the SEC, which identify specific risk factors that may cause actual results to differ materially from those contained in any four looking statements made today. The company does not undertake to update any forward-looking statements as a result of new information or future events or developments. With us on the call today are Dolev Raffaele, Vice Chairman, President, and Chief Executive Officer, and Chris Lesovitz, Chief Financial Officer. Following management's prepared remarks, we will open the call for questions. And with that, I'd now like to turn the call over to Dolev. Go ahead, Dolev.

Thank you, Rich, and good afternoon, everyone. We appreciate you joining us today for our third quarter 2023 Earnings Conference Call. Chris will give an overview of the quarter, after which I will provide remarks on the strategic direction of the business. Before I turn it over to Chris, I first want to address the recent changes in leadership at Strata. The company has undergone a recent reorganization of its board of directors to streamline its structure and enhance its alignment with the company's strategic objectives. As part of the reorganization, Bob Moccia has transitioned from his position as CEO and a member of the board. I am humbled and deeply honored to have accepted the board's offer to serve as vice chairman, president, and CEO. Accumulating over 30 years of experience in healthcare and medical devices, my vision moving forward is to concentrate on advancing and expanding our core products, X-TRAC, B-TRAC, and TheraClearX, by reintroducing our direct-to-consumer, further referred to as BPC, initiative that was in place during my previous three tenures and allowed for clear growth of that business. Some of you may recall that I managed a similar business strategy at the previous public company, growing it by over 300% and subsequently selling said business to Strata in 2015. I later served as Strata's president and CEO from 2018 to 2021. following an investment made into the company by myself and Excelment Growth Partners. That second period was marked by a turnaround of the business's core growth elements. This turnaround helped in shifting the business to become a cash flow positive, growing the domestic and international install base and the corresponding revenue streams, eliminating costs and non-core activities, enhancing the technology by launching new products and filing new patents and making sure the platform was ready for any additional businesses, which, in turn, allowed the company to successfully cross the COVID-19 challenge and be prepared for the core business growth and acquisitions that followed in 2021. As you will see during my remarks later, I believe this will directly increase our recurring revenue and unit utilization, thereby increasing our gross profit margins. It is back to basics here at Strata, and we look forward to your continued support. Now I will turn it over to Chris to review the financials.